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ABSTRACT
OBJECTIVE: The objective of this selective evidence based medicine review is to
determine whether or not “herbal medicine has an effect on the cognitive function of
patients with mild to moderate Alzheimer’s disease over the age of 50”.
STUDY DESIGN: Review of three double-blind, randomized control trials published
between 2003 and 2015. All studies were published in English language in peer reviewed
journals.
DATA SOURCES: Three randomized control trials were found via PubMed.
OUTCOMES MEASURED: The outcomes measured include changes in Alzheimer’s
symptoms based upon a neurologist, improvement of Alzheimer’s symptoms based on
ADAS-cog and CDR-SOB clinical rating scale, and Alzheimer health related quality of
life based on a 20-item questionnaire.
RESULTS: Akhondzadeh et al (2003) demonstrated a significant reduction in
Alzheimer’s symptom scores after treatment with herbal medicine, Salvia officinalis
extract, with a p value of <0.0001. Tajadini et al (2005) demonstrated a significant
reduction in Alzheimer’s symptom scores after treatment with herbal medicine, Davaie
Loban, with a p value of <0.001. Zhang et al (2015) demonstrated a significant reduction
in Alzheimer’s symptom scores after treatment with herbal formula, Yishen Huazbuo
decoction, with a p value of <0.05.
CONCLUSIONS: Results of the three studies demonstrate that herbal medicine is an
effective treatment in individuals over the age of 50 for the cognitive improvement of
mild to moderate Alzheimer’s disease. Two studies recommend that further studies
should be done with longer follow-ups and larger sample sizes to more confidently
confirm the findings.
KEY WORDS: Alzheimer’s disease, herbal medicine, cognitive function
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INTRODUCTION
Alzheimer’s Disease is an irreversible and chronic brain disorder that occurs when brain
tissue is changed and destroys memory and thinking skills. As the population living of the United
States is continuing to age, Alzheimer’s is becoming a more prevalent cause of death5. This
decline happens because neurons that are involved in cognitive function slowly become damaged
over time and do not function properly4. Alzheimer’s is a common disease. Experts suggest that
5.5 million Americans have Alzheimer’s disease and one in nine people age 65 and older are
affected. It is estimated that the total annual healthcare cost for Alzheimer’s disease is $259
billion dollars5. They even state that there are 780 hospital stays per 1,000 Medicare beneficiaries
age 65 and older with Alzheimer’s disease and other dementias4.
The exact cause of Alzheimer’s is unknown; however, it has been found that the
symptoms it causes seem to come from nerve damage. Nerve cells get tangles called
neurofibrillary tangles and protein deposits called beta-amyloid plaques that build up in the
brain. These brain changes are believed to contribute to the development of Alzheimer’s.
Eventually, the number of synapses decrease, information transfer at synapses decline, and
neurons begin to die6. The most common symptoms of Alzheimer’s disease include memory loss
that disrupts daily life, challenges in solving problems, confusion with time and place, trouble
understanding visual images and relationship, and problem with words in both speaking and
writing. There are numerous complications of Alzheimer’s including immobility, swallowing
disorders, malnutrition, and pneumonia4.
There is no cure for Alzheimer’s disease, but medications and sensory therapy can help
its symptoms and slow the progression4. Non-pharmacologic therapies include music therapy and
reminiscence therapy. Previous published research has shown that exercise, gardening, word
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games, and listening to music can show assurance. Lifestyle modifications also include schedule
toileting to reduce incontinence, daily routines, and encourage social interaction4. However,
current pharmacologic therapies as well as non-pharmacologic therapies have not been shown to
alter the viscous course of Alzheimer’s disease. There are different types of drugs that can target
treatment of memory loss, sleep problems, behavior changes, and other symptoms associated
with Alzheimer’s. It is recommended to treat depression and irritability with selective serotonin
reuptake inhibitors (SSRI) such as citalopram (Celexa). For people experiencing anxiety,
medicine such as alprazolam (Niravam, Xanax) may be beneficial. Cholinesterase inhibitors such
as Donezepil (Aricept) are the treatment of choice for people experiencing mild to moderate
symptoms of Alzheimer’s. N-methyl-D-aspartate receptor blocker such as Memantine
(Namenda) is offered to people experiencing more severe symptoms6.
Though there is no cure for Alzheimer’s disease, effective control of the symptoms is an
attainable goal. Despite the existence of effective treatments for sleep problems and behavior
changes, there continues to be an effort to find an effective treatment to improve cognitive
function. It is for this reason that several randomized control trials have been carried out in an
attempt to scientifically show the effectiveness of improving cognitive function with herbal
medicine.
OBJECTIVE
The objective of this selective evidence based medicine review is to determine whether or
not “herbal medicine has an effect on the cognitive function of patients with mild to moderate
Alzheimer’s disease over the age of 50?”
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METHODS
Criteria: This selective evidence based medicine review evaluates three randomized
control trials chosen based on population, intervention, comparison group, and outcomes
measures. The selected population of interest was patients 50 years or older with a diagnosis of
mild to moderate Alzheimer’s disease. The intervention in these three studies was the treatment
of herbal medicines. The treatment group receiving Salvia Officinalis extract, Davaie Loban, or
Chinese herbal formual Yishen Huazbuo decoction was compared to a group receiving a visually
matched placebo or herbal formula donepezil hydrochloride. The outcomes measured in these
studies included the effect on the patient’s cognitive function and activities of daily living.
Data Sources: The key words “Alzheimer’s disease”, “herbal medicine”, and “cognitive
function” were searched on PubMed to find articles both relevant to the clinical question and
ones that included patient oriented outcomes (POEMS: Patient Orientated Evidence that
Matters). All articles were published in the English language between 2003 and 2015 in peerreviewed journals. The inclusion criteria included double-blind studies published after 2000 and
exclusion criteria included patients under 50 years old. The statistics used and reported in the
selective based medicine review include p-value and change in mean from baseline with a
standard deviation.
Table 1- Demographics & Characteristics of Included Studies
Study

Type

Akhond
zadeh,
2003
(1)

Doubleblind,
RCT

#
Pts
39

Age
(years)
Salvia
extract:
71.78 ±
3.67
Placebo
:
72.75 ±
3.43

Inclusion criteria

Exclusion criteria

Patients between 65 and 80,
patients with a history of
cognitive decline for at
least 6 months, diagnosed
with ALZ according to the
NINCDS/ADRDA, ADAScog ≥12 and CDR-SOB ≤2,
any other medication to
treat dementia must be d/c,

Evidence of other
neurodegenerative
disorders, any
cardiovascular
disease, active
peptic ulcer,
urinary outflow
obstruction,
history of

W/
D
9

Interventions
Salvia
officinalis
extract
delivered 60
drops/day for
4 months
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HTN, HF, DM were
included provided the
disease was controlled
Tajadini
2015
(2)

Zhang,
2015
(3)

Doubleblind,
RCT

Doubleblind,
RCT

50

144

Davaie
Loban
66.25
± 6.25
Placebo
:
67.65 ±
5.99
> 50
years
old

Patients older than 50,
diagnosed with mild to
moderate ALZ, ADAScog≥12 and CDR-SOB ≤2,
brain CT or MRI were
examined to rule out multiinfarct dementia or
cerebrovascular diseases
Diagnosis of dementia of
the Alzheimer’s type
according to the diagnostic
and statistical manual,
diagnosis was confirmed by
image test (CT/MRI),
women/men aged 50-85,
Hachinski ischemic score ≤
4, Hamilton depression
rating ≤7, CDR=1

epilepsy, drugs
with
anticholinergic
effects
Cardiovascular
disease, illicit
drug use, DM,
epilepsy,
cerebrovascular
disease,
neurodegenerative
disorders, taking
coagulants
Vascular dementia
or any
neurological
disorder other
than AD that
contributed to
dementia, severe
heart, liverm or
kidney disease,
use of drugs that
may affect
cognitive function
4 weeks prior to
randomization,
uncontrolled
HTN, aphasia,
hemiplegia

6

Davaie Loban
capsules
(500g, three
times daily,
every 8 hours)
for 3 months

31

Chinese herbal
formular
Yishen
Huaxhuo
decoction (100
ml orally once
a day, half an
hour after
breakfast) for
12 months

OUTCOMES MEASURED
All of the outcomes measured in this selective evidence medicine based review include
patient oriented evidence. The outcomes measured include changes in Alzheimer’s symptoms
based upon a neurologist, improvement of Alzheimer’s symptoms based on ADAS-cog and
CDR-SOB clinical rating scale, and Alzheimer health related quality of life based on a 20-item
questionnaire. The ADAS-cog is a 21-item scale used to assess the severity of cognitive
impairments in patients with Alzheimer’s disease. It ranges from 0-70 (very severe) and
evaluates selected aspects of attention, language, memory, orientation, praxis, and reasoning.
The CDR-SOB sums up the ratings from six domains: memory, orientation, judgment, problem
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solving, community affair, home and hobbies, and personal care. It ranges from 0-3 (3=severe
dementia). The Akhondzadeh et al double-blind, randomized control trial measured improvement
of cognitive function in patients with mild-to-moderate Alzheimer’s disease prior to and four
months after the treatment of herbal medicine Salvia officinalis extract. The main efficacy
measures were the ADAS-cog and CDR-SB and outcome measures were the change in ADAScog and CDR-SB scores over the 4-month trial. Patients were evaluated by a neurologist at
baseline and every 2 weeks after the Saliva officinalis extract was administered. The data was
reported as a mean change in baseline with a standard deviation1.
The Tajadini et al double- blind, randomized control trial measured improvement of
cognitive function in patients with mild-to-moderate Alzheimer’s disease prior to and three
months after the treatment of herbal medicine Davaie Loban. This was assessed based on the
ADAS-cog and CDR-SB clinical rating scale every 4 weeks during the study period of 12 weeks.
This data was reported with statistical significant p values.
The Zhang et al double-blind, randomized control trial measured improvement of
cognitive function in patient with mild Alzheimer’s disease prior to and 6 months after the
treatment of herbal formula, Yishen Huazhuo decoction. This was measured using the ADAScog and higher values indicating higher degree of deficit. The study also used a 20-item
questionnaire designed to measure the patient’s ability to carry out daily activities such as
medication management, food preparation, personal hygiene and transportation utilization. Each
of these items rating between 0 and 10, where higher values denote higher severity of symptom.
The data was reported as a mean change in baseline with standard deviation3.
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RESULTS
This selective evidence based medicine review evaluates herbal medicine as a treatment
for Alzheimer’s disease. The results of these studies were all presented in continuous data. All
three studies were randomized with concealment to randomization. All of the patients, clinicians,
and study workers were kept blind to which patients were in the treatment group for the duration
of the study.
Akhondzadeh et al is a double-blind, randomized control trial that assesses the
improvement in cognitive function of herbal medicine Salvia officinalis extract in patients with
mild-to-moderate Alzheimer’s disease who are 50 years and older. The treatment group was
compared to a visually matched placebo group. Thirty-nine participants were placed into one of
the two groups: nineteen patients assigned to the herbal medicine group that received 60
drop/day of S. officinalis extract and twenty patients assigned to the placebo group that received
60 drops/day of placebo. The study measured improvement of cognitive function based on
ADAS-cog and CDR-SOB scores over the trial at baseline and every 2 weeks after. Regarding
both the ADAS-cog and CDR-SOB, there were no significant differences between the two
groups in week 0 (baseline). The difference between the two protocols was significant at the end
point (week 16). The changes at the endpoint compared with baseline for ADAS-cog were: -6.60
+/- 1.63 (mean +/- SD) and 5.53 +/- 1.12 for Salvia extract and placebo, respectively. The
changes at the endpoint compared with baseline for CDR-SOB were: -1.60 +/- 1.35 (mean +/SD) and 0.73 +/- 0.41 for Salvia extract and placebo, respectively. At the conclusion of the
study, it was determined there was a significant increase in cognitive function in Alzheimer’s
patients with a statistically significant p-value of <0.00011.
Figure 2: Mean +/- SEM scores of the two protocols on the ADAS-cog score. ns, non-significant
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Figure 3: Mean +/- SEM scores of the two protocols on the CDR-SB score. ns, non significant

Tajadini et al is a double-blind, randomized control trial that assesses the improvement in
cognitive function of herbal medicine Davaie Loban in patients with mild-to-moderate
Alzheimer’s disease who are 50 years and older. The treatment group was compared to a visually
matched placebo group. Fifty participants were placed into one of the two groups: twenty-five
patients assigned to the herbal medicine Davaie Loban received (500 mg three times daily) and
twenty-five patients assigned to placebo group. The study measured improvement of cognitive
function based on ADAS-cog and CDR-SOB scores over intervention that lasted for 12 weeks.
Regarding the ADAS-cog, there were no significant difference between the two groups in week
0 (baseline) (p=0.751). However, after 4 and 12 weeks there was a significant difference in mean
(SE) ADAS-cog scores between DL and placebo groups and it was lower in DL group
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(p<0.001). Regarding the CDR-SOB, there was no significant decreases between the two groups
in week 0 (baseline) (p=0.096). However, after 4 and 12 weeks there was a significant difference
in mean (SE) CDR-SOB scores between DL and placebo groups and it was lower in DL group
(p<0.001). At the conclusion of the study, it was determined there was a significant increase in
cognitive function in Alzheimer’s patients with a statistically significant p-value of <0.0012.
Fig 2. Mean (SE) scores of ADAS-cog in DL and placebo group throughout study

Fig 3. Mean (SE) scores of CDR-SOB in DL and placebo group throughout study

Zhang et al is a double-blind, randomized control trial that assesses the improvement in
cognitive function of herbal formula Yishen Huazbuo decoction (YHD) in patients with mild
Alzheimer’s disease who are 50 years and older. The treatment group was compared to donepezil
hydrochloride (DH). 144 participants were place into one of the two groups: seventy-two patients
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were assigned to the herbal formula YHD and seventy-two patients were assigned to the DH
group. The study measured improvement of cognitive function based on ADAS-cog and ADL
scores over the intervention that lasted for 24 weeks. The scores in YHD group significantly
reduced in week 12 and 24, while the scores of DH group declined in week 24. The mean scores
of ADAS-cog showed a decreased of 3.10 +/- 4.55 in YHD group and a decrease of 1.22 +/- 4.99
in DH group during the 24 weeks treatment, with statistical significance of p-value <0.053. Both
YHD and DH could improve scores of ADL, but without statistically significant difference
between groups. At the conclusion of the study, it was determined there was a significant
increase in cognitive function in Alzheimer’s patients with a statistically significant p-value of
<0.053.
Fig 2. Scores of ADAS-cog and ADL in YHD and DH group

Table 2. Mean efficacy scores at all time points and change at week 24, 48 (Mean+/-SD)
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DISCUSSION
The three randomized controlled trials discussed in this review suggest that herbal
medicine is an effective alternative treatment for Alzheimer’s disease. All three studies
demonstrated a statistically significant improvement in the cognitive function measured with a
statistical significance threshold set a p<0.05. This study showed that the herbal medicines was
above all else in terms of word recall task, following commands, orientation, word recognition
task, remembering test direction, spoken language, comprehension, and word-finding difficulty.
All three studies in this selective evidence based medicine review demonstrated
limitations. For two of the studies, sample size was the main limitation. Akhondzadeh et al had a
sample size of thirty-nine and Tajadini et al had a sample size of fifty1,2. Another limitation was a
moderate dropout rate. For instance, Akhondzadeh began their study with thirty-nine patients and
ended with thirty1. In the treatment group, 4 discontinued (2 consent withdraw and 2 lost to
follow up) and in the control group, 5 discontinued (1 ineligible to continue, 2 consent withdraw,
2 lost to follow up) thus the outcomes from these people that were not included in the analysis
might have affected the significant of the results1. Tajadini began their study with fifty and ended
with forty-four2. In the treatment group, 1 was lost due to follow up and in the control group, 5
were lost due to follow up, thus the outcomes from these people that were not included in the
analysis might have affected the significance of the results2.
CONCLUSION
All three studies successfully demonstrated that there is a significant improvement in
cognitive function of patients 50 years and older with mild-to-moderate Alzheimer’s disease
following treatment with herbal medicine. Therefore, herbal medicine is an effective alternative
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treatment for improving the cognitive function and reducing the symptoms of Alzheimer’s
disease in patients 50 years and older.
Despite this convincing evidence, further studies on human subjects with longer followups, larger sample sizes, and comparison to chemical drugs currently used for Alzheimer’s
disease should be conducted. It would be important to create a study comparing herbal medicine
to cholinesterase inhibitors or N-methyl-D-aspartate receptor blockers to see which method of
treatment would be superior for treating symptoms of Alzheimer’s disease.
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